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Abstract
Introduction: In cognitively normal (CN) adults, increased rates of amyloid beta (Aβ)
accumulation can be detected in low Aβ (Aβ–) apolipoprotein E (APOE) ε4 carriers. We
aimed to determine the effect of ε4 on the ability to benefit from experience (ie, learn)
in Aβ– CNs.
Methods: Aβ– CNs (n = 333) underwent episodic memory assessments every 18
months for 108 months. A subset (n = 48) completed the Online Repeatable Cognitive
Assessment-Language Learning Test (ORCA-LLT) over 6 days.
Results: Aβ– ε4 carriers showed significantly lower rates of improvement on episodic
memory over 108 months compared to non-carriers (d = 0.3). Rates of learning on
the ORCA-LLT were significantly slower in Aβ– ε4 carriers compared to non-carriers
(d = 1.2).
Discussion: In Aβ– CNs, ε4 is associated with a reduced ability to benefit from experience. This manifested as reduced practice effects (small to moderate in magnitude)
over 108 months on the episodic memory composite, and a learning deficit (large in
magnitude) over 6 days on the ORCA-LLT. Alzheimer’s disease (AD)–related cognitive
abnormalities can manifest before preclinical AD thresholds.
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INTRODUCTION
RESEARCH IN CONTEXT

In cognitively normal (CN) older adults, elevated amyloid beta (Aβ+)
is associated with episodic memory dysfunction, hippocampal volume

Systematic Review: The authors reviewed the litera-

loss, accumulation of Aβ, and increased rate of progression to mild cog-

ture using traditional (eg, PubMed) sources, meet-

nitive impairment (MCI) or dementia, relative to matched adults with

ing abstracts, and presentations. Studies reporting

low Aβ (Aβ–).1,2 The severity of these clinical and biological manifes-

on the role of apolipoprotein E (APOE) in low amy-

tations of Aβ+ is increased further by the apolipoprotein E (APOE)

loid beta (Aβ)– cognitively normal older adults were

ε4 allele3,4 proposed to be a consequence of ε4 disrupting normal Aβ

included. Studies on practice effects in the context

clearance.5 Subtle but increased rates of Aβ accumulation over 3 to

of aging and Alzheimer’s disease (AD) were also

4 years can also be detected in ε4 carriers who remain Aβ–,6 raising

reviewed.

the possibility that cognitive changes may be detectable in Aβ– ε4 carri-

Interpretation: Our findings are novel in showing that

ers if the study design or cognitive assessments applied have sufficient

reduced ability to benefit from experience (ie, learn)

sensitivity.

is evident in Aβ– ε4 carriers. This manifested as

In the Australian Imaging, Biomarkers and Lifestyle (AIBL) study,

reduced practice effects over 108 months on the

CNs completed seven neuropsychological assessments over 108

episodic memory composite, albeit of a small-to-

months providing greater power than previous investigations of Aβ–

moderate magnitude, and a learning deficit that

groups to understand the effects of ε4 on cognition.3,7 However,

was large in magnitude over 6 days on the Online

prospective investigations of cognitive change in AIBL, and in simi-

Repeatable Cognitive Assessment-Language Learn-

lar longitudinal cohorts, now show that in Aβ+ CNs, episodic memory

ing Test (ORCA-LLT).

remains stable over 5 to 6 years, whereas in matched Aβ– CNs, memory

Future Directions: Future studies are required to deter-

improves substantially over the same interval (ie, a practice effect).8–11

mine the extent to which other neuroinflammatory,

Reduced practice effects are proposed to be a strong clinical marker of

cerebrovascular, or neurodegenerative processes

early Alzheimer’s disease (AD) pathologic changes in preclinical AD,9,11

may be related to this learning deficit in Aβ– adults.

and are therefore likely to occur in CN Aβ– ε4 carriers. However, we
have argued that a more parsimonious conceptualization of observations of reduced practice effects is that in very early AD, deficits in the
ability to benefit from experience (ie, to learn) are greater than deficits
in memory retrieval; at least as when measured by standardized tests

Contacted n=184

of episodic memory.10,12 We challenged this hypothesis in preclinical

No access to computer = 8
Terminal cancer = 1
Training in Chinese = 4

AD, and found that deficits on a formal learning paradigm, evident over
6 days, were four times greater than the abnormal change in episodic
memory detected across the prior 6 years.12 Application of this learning model may therefore also inform understanding of any AD-related

Eligible = 169

cognitive dysfunction in CN Aβ– ε4 carriers.

Not interested = 64

2
2.1

METHODS
Participants

Enrolled = 105
Withdrew = 8
Too burdensome = 4
Not interested = 3
No longer has access to computer = 1

Aβ– CN older adults (n = 333) enrolled in the AIBL study provided a
blood sample for APOE genotyping, and underwent serial neuropsychological assessments every 18 months, for at least three timepoints.
A subgroup of these participants (n = 48), naïve to Chinese, Japanese

Completed tesng
= 89

or Korean languages, also participated in a 6-day learning challenge
(Figure 1 summarizes the number of participants contacted, eligible,
enrolled, and included in this analysis). No participant had progressed

Aβ- (n=48)

to MCI/AD. Recruitment and inclusion/exclusion criteria of AIBL have
been described previously.13,14 A clinical panel comprised of geriatricians, neurologists, and neuropsychologists determined the cognitive normality of participants by examining all available medical and

F I G U R E 1 Flowchart of the number of participants contacted,
enrolled, and completed Online Repeatable Cognitive
Assessment-Language Learning Test (ORCA-LLT)
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TA B L E 1

Demographic, clinical, cardiovascular, and neuroimaging characteristics
AIBL CN sample
Aβ- ε4(n = 273)

ORCA CN subsample
Aβ- ε4+
(n = 60)

Aβ- ε4(n = 35)

Aβ- ε4+
(n = 13)

Mean (SD)

Mean (SD)

p

Mean (SD)

Mean (SD)

p

N, Female (%)

154 (46.2)

33 (55.0)

.842

18 (60.0)

5 (41.7)

.281

Age at first assessment, y

69.37 (5.87)

67.69 (5.51)

.044

74.40 (4.93)

73.85 (5.24)

.735

Years of education

12.36 (2.96)

12.48 (3.05)

.790

13.85 (2.87)

12.15 (3.11)

.083

HADS-anxiety†

4.42 (2.85)

4.79 (3.58)

.472

3.65 (2.97)

4.00 (3.70)

.735

HADS-depression†

2.60 (2.25)

3.11 (2.44)

.211

2.32 (2.23)

3.08 (2.66)

.331

MMSE†

28.86 (1.20)

28.94 (1.10)

.616

29.12 (1.04)

29.15 (1.21)

.919

CDR Sum of Boxes†

0.03 (0.16)

0.04 (0.14)

.736

0.04 (0.19)

0.19 (0.43)

.108

Body mass index

26.87 (4.15)

26.25 (3.61)

.305

26.45 (3.67)

25.39 (3.17)

.433

Abdominal circumference, cm

92.98 (13.28)

92.44 (13.19)

.790

89.66 (11.27)

90.70 (7.62)

.795

Diastolic blood pressure, mmHg

79.15 (10.33)

77.24 (8.73)

.192

81.48 (9.18)

78.60 (7.72)

.394

Systolic blood pressure, mmHg

136.52 (15.34)

139.19 (15.22)

.230

136.74 (15.99)

136.80 (7.76)

.991

Centiloid†

1.71 (9.87)

2.70 (9.69)

.481

0.92 (4.63)

-0.60 (10.13)

.478

Hippocampal volume, cm †

2.95 (0.29)

2.97 (0.25)

.686

2.94 (0.25)

3.01 (0.28)

.426

N years between first PET scan and baseline
AIBL cognitive assessment

3.28 (2.54)

2.61 (2.39)

.064

–

–

–

N years between most recent PET scan and
ORCA assessment

–

–

–

1.31 (1.22)

0.94 (0.84)

.319

N AIBL cognitive assessments

6.14 (1.20)

6.27 (1.12)

.464

5.21 (2.31)

4.69 (2.18)

.492

3

Abbreviations: AIBL, Australian Imaging, Biomarkers and Lifestyle Study; CDR, Clinical Dementia Rating; CN, cognitively normal; HADS, Hospital Anxiety
and Depression Scale; MMSE, Mini-Mental State Examination; ORCA, Online Repeatable Cognitive Assessment; PET, positron emission tomography; SD,
standard deviation.
† obtained from the PET scan for the AIBL CN sample and closest PET scan to ORCA-LLT assessment for the ORCA subsample; bolded values are significant
at P < .05.

neuropsychological information. This clinical panel was blind to genetic

30-minute delayed recall trial were standardized using the baseline

and neuroimaging information. Participants were classified as cogni-

mean and standard deviation of the Aβ– CN group, and averaged. As

tively normal if they performed greater than –1 standard deviation on

has been reported previously, identical forms of these memory tests

all neuropsychological tests when compared to Australian norms, had

were used at each assessment timepoint (administered in 18-month

a Mini-Mental State Examination (MMSE) score of 26 or greater, and

intervals).16,17

a Clinical Dementia Rating (CDR) sum of boxes score of 0 or 0.5 (CDR
sum of boxes score of 0.5 was acceptable if all neuropsychological tests
were within normative ranges). Demographic characteristics are sum-

2.3

Learning test

marized in Table 1.
The AIBL study was approved by institutional research and ethics
committees.14

Human research ethics approval to conduct this study

was obtained through Melbourne Health.15

Informed consent was pro-

vided in writing prior to participation in this study.

The Online Repeatable Cognitive Assessment-Language Learning Test
(ORCA-LLT) has also been described.12,15 This test measured the ability to learn the English language equivalent of 50 Chinese characters
over six sessions. Participants were required to determine whether
the English word and Chinese character had the same meaning. Sessions consisted of two blocks of 200 trials of both correct and incor-

2.2

Episodic memory composite

rect pairs with each block requiring approximately 10 minutes to
complete. Within each block, each Chinese character was presented

The rationale and validation of the AIBL episodic memory comdescribed.3

four times in random order. For two of these presentations, the Chi-

Raw scores on the California Verbal

nese character was paired with the correct spoken English word.

Learning Test, Second Edition (CVLT-II) delayed recall trial, the Logical

For the remaining two presentations, incorrect spoken English words

Memory delayed recall trial, and the Rey Complex Figure Test (RCFT)

were selected at random from the other possible 49 words. Each

posite has been
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day of the task provided unique sets of incorrect pairings, while the

the ORCA-LLT was determined using a linear mixed-effects model. For

correct pairings stayed constant over time, to prevent off-target learn-

the ORCA-LLT, the Akaike information criterion (AIC) for the linear and

ing of incorrect pairs. Thus, the ratio of correct to incorrect pairings for

quadratic models were 1534.18 and 1554.17, respectively, with the lin-

the first day was 4:2, for the second day was 8:2, for the third day was

ear model demonstrating a significantly better fit (lower AIC values),

12:2, for the fourth day was 16:2, for the fifth day was 20:2, and for

χ2 = 52.99, P < .001. Similarly, for the episodic memory composite, the

the final day was 24:2. The order of trials was randomized for each ses-

AIC for the linear and quadratic models were 4023.22 and 4042.91,

sion and participant. Participants were unaware of the underlying ratio

with the quadratic model not significantly better than the linear model,

of correct to incorrect pairings, and no feedback regarding accuracy of

χ2 = 1.53, P = .465. Age was included as a covariate in all models. The

the decision was provided to participants. The primary outcome of the

unit of time for both mixed-effects models was test session (ie, months

ORCA-LLT was accuracy (percentage of correct responses).

for the episodic memory composite and days for ORCA-LLT). Cohen’s d
was used to express the magnitude of between-group differences.

2.4

Neuroimaging
3

RESULTS

Aβ imaging with positron emission tomography (PET) was conducted
using one of four radioligands: Pittsburgh Compound B, florbetapir,

3.1

Sample characteristics

flutemetamol, or navidea. The acquisition protocol for each radioligand
has been detailed previously.13,18 Threshold values for elevated Aβ

APOE ε4 carriers were slightly younger than ε4 non-carriers, but were

deposition varied by radiotracer, so all standardized uptake value ratios

equivalent on other demographic, clinical, cardiovascular, and neu-

(SUVR) were transformed onto the Centiloid scale using CapAIBL.19,20

roimaging characteristics (Table 1). In the ORCA sub-sample, ε4 carriers

Aβ– was classified if Centiloid scores were <15 at the closest imag-

and non-carriers were matched on all demographic, clinical and neu-

ing visit relative to participants’ AIBL baseline cognitive assessment or

roimaging characteristics. The average completion rate for the ORCA-

ORCA assessment.

LLT was 98% across all days, with the lowest completion rate observed
on Day 6 (ie, 96%).

2.4.1

Procedure

Participants completed the AIBL neuropsychological battery every 18

3.2
Effect of APOE ε4 on episodic memory
and short-term learning

months. A subgroup completed the ORCA-LLT in their own homes
through a web-based application using either a laptop or desktop com-

For the episodic memory composite, a significant ε4 x time interaction

puter daily for 6 days. Assessors of the AIBL neuropsychological bat-

was observed. Decomposition of the interaction indicated that Aβ– CN

tery and the ORCA-LLT were blind to Aβ neuroimaging and genetic

ε4 carriers demonstrated a significantly slower rate of improvement

results.

over 108 months compared to Aβ– CN ε4 non-carriers (Figure 2A). This
difference was small to moderate in magnitude (Table 2). Analyses of
the ORCA-LLT learning curves indicated that ε4 carriers showed sig-

2.5

Data analysis

nificantly slower rates of learning compared to ε4 non-carriers (modeled data in Figure 2B; raw data in Figure 2C), with the difference

Analyses were conducted using R v.3.5.0. Although data distributions

large in magnitude (Table 2). Re-analyses of the ORCA-LLT learning

for raw proportion correct performance scores on the ORCA-LLT were

curves using untransformed data also yielded a significant interaction

distributed normally (Shapiro-Wilks test, Ps > .100 for all days), an arc-

between APOE ε4 and time, albeit with a smaller effect size, d (95% con-

sine square-root transformation was applied prior to analyses. Arc-

fidence interval) = 1.18 (0.48, 1.84), P < .001.

sine square-root transformations are used commonly for analyses of
proportion correct scores as they increase the range of possible values when scales are bounded by chance (ie, 50%) and a perfect score

4

DISCUSSION

(ie, 100%), which in turn can increase statistical power.21 To ensure
that this normalization did not distort outcomes, we repeated analyses

Our study shows that in Aβ– CN older adults, the APOE ε4 allele is

using raw proportion correct data to determine the similarity of con-

associated with a reduced ability to learn, or put more broadly, as a

clusions drawn from analyses using transformed data.

reduced ability to benefit from experience. One manifestation of this

Differences between APOE ε4 carriers and non-carriers in the rate

is a reduction in the practice effect expected from 9 years of retesting

of change on the episodic memory composite were determined using a

on neuropsychological tests that yield the AIBL episodic memory com-

linear mixed-effects model (unstructured covariance matrix, maximum

posite (Figure 2A). However, despite the considerable length of follow-

likelihood estimation, participant as random factor). Similarly, the dif-

up, number of reassessments using the same versions of the memory

ference between ε4 carriers and non-carriers on the rate of learning on

tests, and sample size, the magnitude of the reduced practice effect in

5 of 7
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F I G U R E 2 Effect of APOE ε4 on episodic memory performance over 108 months modeled using unadjusted estimates (A), and ORCA-LLT
performance over 6 days, modeled using linear mixed model (B), and raw group means (C). Shaded areas and error bars represent 95% confidence
intervals. Aβ, amyloid beta; APOE, apolipoprotein E; ORCA-LLT, Online Repeatable Cognitive Assessment-Language Learning Test

TA B L E 2 Mean slopes (SD) and Cohen’s d representing group mean slope differences from the mixed-effects model on episodic memory
performance in the broader AIBL sample, and accuracy of performance on the ORCA-LLT
AIBL CN full sample (outcome: EM
composite)

ORCA CN subsample (outcome: ORCA-LLT
accuracy)

β (SE)

β (SE)

P

P

APOE ε4

–0.195 (0.117)

.096

–0.311 (0.184)

.097

Age

–0.291 (0.045)

<.001

–0.028 (0.082)

.734

0.148 (0.013)

<.001

0.752 (0.020)

<.001

–0.068 (0.031)

.027

–0.147 (0.040)

<.001

Time
APOE ε4 × Time

Mean (SD)

N

Mean (SD)

N

Aβ- ε4 non-carrier

0.148 (0.215)

273

0.752 (0.118)

35

Aβ- ε4 carrier

0.079 (0.215)

60

0.604 (0.126)

13

Cohen’s d (95% CI)

0.32 (0.04, 0.60)

1.23 (0.53, 1.89)

Abbreviations: AIBL, Australian Imaging, Biomarkers and Lifestyle (AIBL) study; APOE, apolipoprotein E; CI, confidence interval; CN, cognitively normal;
EM, Episodic memory; ORCA-LLT, Online Repeatable Cognitive Assessment-Language Learning Test; SD, standard deviation; SE, standard error.
Notes: Bolded values are significant at P < .05; all β estimates reported have been standardized.

the Aβ– CN ε4 group was only small to moderate (d = 0.3). More proac-

nese character-English word pairs, with the magnitude of this reduc-

tively, in ε4 carriers, the reduced ability to benefit from experience was

tion much larger (d = 1.2) than that observed for the episodic memory

evident from only 6 days of testing on the ORCA-LLT. In the ORCA

composite (Figure 2B).

paradigm, the failure to benefit from experience manifested in the sub-

Reduced practice effects on episodic memory tests have been

stantially lower ability of the Aβ– CN ε4 carriers to learn a set of 50 Chi-

observed previously in preclinical AD groups from AIBL and other
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prospective studies,8–10 although the magnitude of these reductions

studies to determine whether the nature and magnitude of learning

(d = 0.4) have been only slightly larger than those observed between

rates change over time.

the current sample of Aβ– ε4 carriers and non-carriers. Recent inves-

These limitations notwithstanding, the consistent observation that

tigations into Aβ– individuals have identified subsets with faster Aβ

AD risk factors such as Aβ accumulation and APOE ε4 are associated

accumulation,7 particularly in ε4 carriers,6 although no study has

with substantial learning deficits, that can be detected over days, sup-

observed memory decline in either AD risk groups when individuals

ports the hypothesis that cognitive dysfunction in early AD manifests

progressed to MCI/AD were excluded.7

The large deficit in learn-

as a failure to benefit from experience. Furthermore, the presence of

ing observed in Aβ– ε4 carriers on the ORCA-LLT is qualitatively similar

this large learning deficit in Aβ– CN ε4 carriers shows, perhaps for the

to that reported previously, albeit with a slightly reduced magnitude,

first time, that AD-related clinical abnormalities can manifest strongly

in the comparison of older adults with preclinical AD to Aβ– controls

in CN individuals even before they reach thresholds that currently

(ie, d >

define preclinical AD.

who

2).12

While this learning deficit likely reflects the deleterious

effects of accumulating Aβ on the neurons or synapses necessary for
the acquisition of new information, the precise biological basis of this
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completion (98%) on the ORCA-LLT. Additionally, our previous observation that short-term learning deficits in preclinical AD were very
large (d > 2),12 which provided reassurance that even with this relatively small sample size, we would have sufficient power to observe
a qualitatively similar deficit in Aβ– ε4 carriers. When considered
together with the reduced practice effect observed over years, the
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